<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04977336</url>
  </required_header>
  <id_info>
    <org_study_id>VX21-548-101</org_study_id>
    <nct_id>NCT04977336</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating&#xD;
      acute pain after a bunionectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-weighted sum of Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) 0 to 48 Hours (SPID48) After the First Dose of Study Drug</measure>
    <time_frame>0 to 48 Hours After the First Dose of Study Drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-weighted SPID as Recorded on a NPRS 0 to 24 Hours (SPID24) After the First Dose of Study Drug</measure>
    <time_frame>0 to 24 Hours After the First Dose of Study Drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of Participants With &gt;=30 Percent (%), &gt;=50%, and &gt;=70% Reduction in NPRS at 48 Hours After the First Dose of Study Drug</measure>
    <time_frame>At 48 Hours After the First Dose of Study Drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of VX-548</measure>
    <time_frame>Pre-dose to 12 Hours and 24 to 36 Hours After the First Dose of Study Drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of VX-548</measure>
    <time_frame>Pre-dose to 12 Hours and 24 to 36 Hours After the First Dose of Study Drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Versus Time Curve During a Dosing Interval (AUCtau) of VX-548</measure>
    <time_frame>Pre-dose to 12 Hours and 24 to 36 Hours After the First Dose of Study Drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 up to Day 18</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>VX-548</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive different dose levels of VX-548.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrocodone bitartrate/acetaminophen (HB/APAP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive HB/APAP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebos matched to VX-548 and HB/APAP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-548</intervention_name>
    <description>Tablets for oral administration.</description>
    <arm_group_label>VX-548</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB/APAP</intervention_name>
    <description>Capsules for oral administration.</description>
    <arm_group_label>Hydrocodone bitartrate/acetaminophen (HB/APAP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (matched to VX-548)</intervention_name>
    <description>Placebo matched to VX-548 for oral administration.</description>
    <arm_group_label>Hydrocodone bitartrate/acetaminophen (HB/APAP)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (matched to HB/APAP)</intervention_name>
    <description>Placebo matched to HB/APAP for oral administration.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>VX-548</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Before Surgery:&#xD;
&#xD;
               -  Participant scheduled to undergo a primary unilateral bunionectomy with distal&#xD;
                  first metatarsal osteotomy (i.e., Austin procedure) and internal fixation under&#xD;
                  regional anesthesia (Mayo and popliteal sciatic block)&#xD;
&#xD;
          -  After Surgery:&#xD;
&#xD;
               -  Participant is lucid and able to follow commands&#xD;
&#xD;
               -  All analgesic guidelines were followed during and after the bunionectomy&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Before Surgery:&#xD;
&#xD;
               -  Prior history of bunionectomy or other foot surgery on the index foot&#xD;
&#xD;
               -  History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)&#xD;
&#xD;
               -  Any prior surgery within 1 month before the first study drug&#xD;
&#xD;
          -  After Surgery:&#xD;
&#xD;
               -  Participant had a Type 3 deformity requiring a base wedge osteotomy or&#xD;
                  concomitant surgery such as hammertoe repair, or had medical complications during&#xD;
                  the bunionectomy that, in the opinion of the investigator, should preclude&#xD;
                  randomization&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>617-341-6777</phone>
    <email>medicalinfo@vrtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lotus Clinical Research</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chesapeake Research Group</name>
      <address>
        <city>Pasadena</city>
        <state>Maryland</state>
        <zip>21122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Surgical Hospital</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Legent Orthopedic Hospital</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>JBR Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

